Akebia Therapeutics, Inc. Common Stock (NASDAQ: AKBA) last traded at $0.801, down 1.68% on the session. The quote above updates while this page is open; the figures below are drawn from Akebia Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Akebia Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker AKBA. Its market capitalisation is $221.99 million.
Valuation measures for Akebia Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $221.99M |
|---|---|
| Enterprise value | $391.08M |
| Price / sales | 1.01 |
| Price / book | 8.87 |
| Beta | 1.12 |
Trailing-twelve-month figures tagged in Akebia Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $219.06M |
|---|---|
| Net income (TTM) | -$29.67M |
| EPS (TTM) | -$0.110 |
| Gross margin | 79.63% |
| Operating margin | -6.90% |
| Return on equity | -118.58% |
| Cash | $155.55M |
Range and volume for AKBA over the past 52 weeks.
| 52-week high | $3.20 |
|---|---|
| 52-week low | $0.801 |
| Volume | 6.09M |
| Average volume | 6.18M |
| Previous close | $0.815 |
Invest a chosen dollar amount in Akebia Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell AKBA.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.